Yasuhito Terui

Phase I/II study of tirabrutinib, a second-generation Bruton’s tyrosine kinase inhibitor, in relapsed/refractory primary central nervous system lymphoma

Yoshitaka Narita, Motoo Nagane, Kazuhiko Mishima et al. · Neuro-Oncology · 2020 · 184 citations · Full text

Medicine, Oncology, Pharmacology +17

Prognostic value of end-of-induction PET response after first-line immunochemotherapy for follicular lymphoma (GALLIUM): secondary analysis of a randomised, phase 3 trial

Judith Trotman, Sally F. Barrington, David Belada et al. · The Lancet Oncology · 2018 · 159 citations · Full text

Medicine, Immunology, Oncology +13

Frontline bortezomib, rituximab, cyclophosphamide, doxorubicin, and prednisone (VR-CAP) versus rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) in transplantation-ineligible patients with newly diagnosed mantle cell lymphoma: final overall survival results of a randomised, open-label, phase 3 study

Tadeusz Robak, Jie Jin, Halyna Pylypenko et al. · The Lancet Oncology · 2018 · 140 citations

Medicine, Hematology, Oncology +15

Lymphomatoid gastropathy: a distinct clinicopathologic entity of self-limited pseudomalignant NK-cell proliferation

Kengo Takeuchi, Masahiro Yokoyama, Shin Ishizawa et al. · Blood · 2010 · 128 citations · Full text

Medicine, Oncology, Pathology +14

Circulating tumor cells as a surrogate marker for determining response to chemotherapy in patients with advanced gastric cancer

Satoshi Matsusaka, Keisho Chìn, Mariko Ogura et al. · Cancer Science · 2010 · 121 citations · Full text

Medicine, Oncology, Pharmacology +17